Trial Profile
Phase I/II trial of NSI 566 for the treatment of motor deficits caused by ischaemic stroke
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs NSI 566 (Primary)
- Indications Paralysis
- Focus Adverse reactions
- Sponsors Neuralstem China; Seneca Biopharma
- 01 Jul 2019 According to a Neuralstem media release, results from the phase I portion of this study was published in the Stem Cells Translational Medicine.
- 01 Jul 2019 Results(n=9) of the phase I portion of this study published in the Neuralstem Media Release
- 01 Jul 2019 According to a Neuralstem media release, the principal investigator of this study is Professor Xu Ruxiang.